Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report
Top Cited Papers
Open Access
- 1 June 2006
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 6 (6), 1377-1386
- https://doi.org/10.1111/j.1600-6143.2006.01290.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 YearsCirculation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsThe New England Journal of Medicine, 2003
- The influence of cyclosporine on mycophenolic acid plasma concentrations: a reviewTransplantation Reviews, 2003
- Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocolTransplantation, 2002
- Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in hearttransplant recipientsTransplantation Proceedings, 2002
- TacrolimusDrugs, 2000
- A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimusThe Journal of Heart and Lung Transplantation, 1999
- A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1Transplantation, 1998
- Effect of Pravastatin on Outcomes after Cardiac TransplantationThe New England Journal of Medicine, 1995
- Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factorsThe American Journal of Cardiology, 1994